Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schiff

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Rheumatology and Therapy|October 24, 2019
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)Roy Fleischmann, Michael Weinblatt, Harris Ahmad, et al.
Plant Molecular Biology|September 10, 2004
Virus induced gene silencing of a DEFICIENS ortholog in Nicotiana benthamianaYule Liu, Naomi Nakayama, Michael Schiff, et al.
The Journal of Rheumatology|July 17, 2012
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapyMark C Genovese, Michael Schiff, Michael Luggen, et al.
RMD Open|June 30, 2018
Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohortRuediger B Mueller, Toni Kaegi, Sarah R Haile, et al.
Arthritis Care & Research|October 17, 2015
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid ArthritisRoy Fleischmann, Michael E Weinblatt, Michael Schiff, et al.
RMD Open|April 26, 2016
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease durationMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Advances in Therapy|August 6, 2018
A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and ConsequencesNikos Maniadakis, Emese Toth, Michael Schiff, et al.
Journal of Clinical Medicine|March 14, 2018
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM CohortKatja Heinimann, Johannes von Kempis, Rafael Sauter, et al.
Annals of the Rheumatic Diseases|August 29, 2006
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialMichael Weinblatt, Michael Schiff, Allan Goldman, et al.
Plos Biology|February 15, 2007
A novel role for the TIR domain in association with pathogen-derived elicitorsTessa M Burch-Smith, Michael Schiff, Jeffrey L Caplan, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Rheumatology and Therapy|October 24, 2019
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)Roy Fleischmann, Michael Weinblatt, Harris Ahmad, et al.
Plant Molecular Biology|September 10, 2004
Virus induced gene silencing of a DEFICIENS ortholog in Nicotiana benthamianaYule Liu, Naomi Nakayama, Michael Schiff, et al.
The Journal of Rheumatology|July 17, 2012
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapyMark C Genovese, Michael Schiff, Michael Luggen, et al.
RMD Open|June 30, 2018
Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohortRuediger B Mueller, Toni Kaegi, Sarah R Haile, et al.
Arthritis Care & Research|October 17, 2015
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid ArthritisRoy Fleischmann, Michael E Weinblatt, Michael Schiff, et al.
RMD Open|April 26, 2016
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease durationMichael Schiff, Michael E Weinblatt, Robert Valente, et al.
Advances in Therapy|August 6, 2018
A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and ConsequencesNikos Maniadakis, Emese Toth, Michael Schiff, et al.
Journal of Clinical Medicine|March 14, 2018
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM CohortKatja Heinimann, Johannes von Kempis, Rafael Sauter, et al.
Annals of the Rheumatic Diseases|August 29, 2006
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialMichael Weinblatt, Michael Schiff, Allan Goldman, et al.
Plos Biology|February 15, 2007
A novel role for the TIR domain in association with pathogen-derived elicitorsTessa M Burch-Smith, Michael Schiff, Jeffrey L Caplan, et al.
Pageof 9